1 not yet recruiting, 1 recruiting. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow camrelizumab: new trials by email Literature Review of camrelizumab trials Research Report on camrelizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study) Paclitaxel Oral Solution, PD-1/PD-L1 inhibitor (eg. Tislelizumab) - Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 4 | Recruiting | Anhui Provincial Cancer Hospital | 107 | 2026-07-24 | 2026-08-04 |
| A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Camrelizumab + chemotherapy+Thalidomide, Camrelizumab + chemotherapy+placebo - Lung Cancer, Camrelizumab | Phase 4 | Not yet recruiting | Tongji University | 104 | 2024-02-22 | 2024-02-26 |
Lung Neoplasms (1) · Small Cell Lung Carcinoma (1)
Anhui Provincial Cancer Hospital (1) · Tongji University (1)
China (1)
Anwen Xiong, MD (1) · Yueyin Pan, MD, PhD (1)
PMID 26028407, PMID 26291008, PMID 27413711, PMID 28196905, PMID 30280641, PMID 31590988, PMID 32599071, PMID 33333328, PMID 33538338, PMID 35576956, PMID 36166026, PMID 38460751